Xeris Biopharma Holdings (XERS) FCF Margin (2020 - 2026)

Xeris Biopharma Holdings has reported FCF Margin for 7 years, with the latest figure at 11.87% in Q1 2026.

• For the quarter ending Q1 2026, FCF Margin rose 2856.0% year-over-year to 11.87%; the trailing twelve-month figure through Mar 2026 stood at 15.41% (up 2741.0% YoY), and the FY2025 full-year result was 9.81%, up 2802.0% from the prior year.
• FCF Margin for Q1 2026 stood at 11.87%, down from 23.36% in the prior quarter.
• The five-year high for FCF Margin was 24.78% in Q3 2025, with the low at 219.31% in Q1 2022.
• Historically, FCF Margin has averaged 33.96% across 5 years, with a median of 21.53% in 2024.
• Annual changes were most pronounced in 2022 — FCF Margin jumped 14471 bps — and 2024, when it plunged 1354 bps.
• Xeris Biopharma Holdings' FCF Margin stood at 48.63% in 2022, then surged by 135 bps to 16.83% in 2023, then plunged by 80 bps to 3.29% in 2024, then jumped by 611 bps to 23.36% in 2025, then slumped by 49 bps to 11.87% in 2026.
• The last three FCF Margin figures came in at 11.87% (Q1 2026), 23.36% (Q4 2025), and 24.78% (Q3 2025), per Business Quant data.